ArticleFrontiers in immunology2022
A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- LncRNA expression signature correlated with cuproptosis: prognostic implications and insights into immune microenvironment in ovarian cancer.Journal of molecular histology · 2026Article
- Integrative single-cell and bulk transcriptomics uncovers a lipid metabolism-related lncRNA signature alongside the ELFN1-AS1/LYPLA1 axis driving osteosarcoma progression.Frontiers in immunology · 2026Article
- Construction and validation of an anoikis-related long non-coding RNA-based prognostic model for head and neck squamous cell carcinoma.Translational cancer research · 2025Article
- Immune infiltration and drug treatment response of angiogenesis-related LncRNA in lung adenocarcinoma.Medicine · 2025Article
- Identification of a cuproptosis‑related prognostic biomarker and therapeutic target in ovarian cancer.Oncology letters · 2025Article
- Targeting cuproptosis for cancer therapy: Focus on the anti-tumor immune system.Cancer pathogenesis and therapy · 2025Review
- PANoptosis-related genes in the prognosis and immune landscape of hepatocellular carcinoma.Immunologic research · 2025Article
- Big data analysis and machine learning of the role of cuproptosis-related long non-coding RNAs (CuLncs) in the prognosis and immune landscape of ovarian cancer.Frontiers in immunology · 2025Article
- Subtype cluster analysis unveiled the correlation between m6A- and cuproptosis-related lncRNAs and the prognosis, immune microenvironment, and treatment sensitivity of esophageal cancer.Frontiers in immunology · 2025Article
- Construction of a cuproptosis-tricarboxylic acid cycle-associated lncRNA model to predict the prognosis of non-small cell lung cancer.Translational cancer research · 2024Article
- Construction of a disulfidptosis-associated lncRNA signature to predict prognosis in bladder cancer.Translational andrology and urology · 2024Article
- Exploration on the construction of a bladder cancer prognostic model based on disulfidptosis-related lncRNAs and its clinical significance.Scientific reports · 2024Article
- Gene Expression Regulation and the Signal Transduction of Programmed Cell Death.Current issues in molecular biology · 2024Review
- A novel mitochondrial-related lncRNA signature mediated prediction of overall survival, immune landscape, and the chemotherapeutic outcomes for bladder cancer patients.Discover oncology · 2024Article
- Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.Scientific reports · 2024Article
- Bioinformatics analysis and experimental validation of m6A and cuproptosis-related lncRNA NFE4 in clear cell renal cell carcinoma.Discover oncology · 2024Article
- Identification and validation of a novel risk model based on cuproptosis‑associated m6A for head and neck squamous cell carcinoma.BMC medical genomics · 2024Article
- Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis.Journal of hematology & oncology · 2024Review
- Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.BMC gastroenterology · 2024Article
- Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.BMC urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BLCA) is one of the deadliest diseases, with over 550,000 new cases and 170,000 deaths globally every year. Cuproptosis is a copper-triggered programmed cell death and is associated with the prognosis and immune response of various cancers. Long non-coding RNA (lncRNA) could serve as a prognostic biomarker and is involved in the progression of BLCA. Methods: The gene expression profile of cuproptosis-related lncRNAs was analyzed by using data from The Cancer Genome Atlas. Cox regression analysis and least absolute shrinkage and selection operator analysis were performed to construct a cuproptosis-related lncRNA prognostic signature. The predictive performance of this signature was verified by ROC curves and a nomogram. We also explored the difference in immune-related activity, tumor mutation burden (TMB), tumor immune dysfunction and exclusion (TIDE), and drug sensitivity between the high- and low-risk groups. Results: We successfully constructed a cuproptosis-related lncRNA prognostic signature for BLCA including eight lncRNAs (RNF139-AS1, LINC00996, NR2F2-AS1, AL590428.1, SEC24B-AS1, AC006566.1, UBE2Q1-AS1, and AL021978.1). Multivariate Cox analysis suggested that age, clinical stage, and risk score were the independent risk factors for predicting prognosis of BLCA. Further analysis revealed that this signature not only had higher diagnostic efficiency compared to other clinical features but also had a good performance in predicting the 1-year, 3-year, and 5-year overall survival rate in BLCA. Notably, BLCA patients with a low risk score seemed to be associated with an inflamed tumor immune microenvironment and had a higher TMB level than those with a high risk score. In addition, patients with a high risk score had a higher TIDE score and a higher half maximal inhibitory concentration value of many therapeutic drugs than those with a low risk score. Conclusion: We identified a novel cuproptosis-related lncRNA signature that could predict the prognosis and immune landscape of BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.